Pediatric TB: Issues related to current and future treatment options

Future Microbiology

Volumn 4, Issue 6, 2009, Pages 661-675

  Marais, Ben J ^a   Schaaf, H Simon ^a   Donald, Peter R ^a  

^a UNIVERSITY OF STELLENBOSCH   (South Africa)

Author keywords

Pediatric TB; Treatment

Indexed keywords

1 (6 BROMO 2 METHOXY 3 QUINOLINYL) 4 DIMETHYLAMINO 2 (1 NAPHTHYL) 1 PHENYL 2 BUTANOL; 2,3 DIHYDRO 2 METHYL 6 NITRO 2 [4 [4 (4 TRIFLUOROMETHOXYPHENOXY) 1 PIPERIDINYL]PHENOXYMETHYL]IMIDAZO[2,1 B]OXAZOLE; 6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMINOSALICYLIC ACID; ANTIRETROVIRUS AGENT; CAPREOMYCIN; ETHAMBUTOL; ETHIONAMIDE; GATIFLOXACIN; ISONIAZID; KANAMYCIN; KRQ 10018; LEVOFLOXACIN; LL 3858; MOXIFLOXACIN; N (2 ADAMANTYL) N' GERANYLETHYLENEDIAMINE; NEVIRAPINE; OFLOXACIN; PROTEINASE INHIBITOR; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; RIFAPENTINE; STREPTOMYCIN; TERIZIDONE; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ARTHRALGIA; BACTERIAL IMMUNITY; BACTERIAL TRANSMISSION; BACTERICIDAL ACTIVITY; CHILDHOOD DISEASE; CHILDHOOD MORTALITY; CLINICAL TRIAL; CONVULSION; DEPRESSION; DIAGNOSTIC ACCURACY; DRUG BLOOD LEVEL; DRUG COMPETITION; DRUG COST; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; DRUG PENETRATION; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; EARLY DIAGNOSIS; ENDEMIC DISEASE; EPIDEMIC; GASTROINTESTINAL SYMPTOM; HEALTH CARE AVAILABILITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOTHYROIDISM; INFECTION PREVENTION; INSOMNIA; LIVER TOXICITY; MILIARY TUBERCULOSIS; MORBIDITY; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NEPHROTOXICITY; NONHUMAN; OPTIC NEURITIS; OTOTOXICITY; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; POLITICS; PRIORITY JOURNAL; PSYCHOSIS; RECOMMENDED DRUG DOSE; REVIEW; SHORT COURSE THERAPY; SINGLE DRUG DOSE; TOXIC HEPATITIS; TUBERCULOSIS; TUBERCULOUS MENINGITIS; VISUAL DISORDER; VOMITING;

ADOLESCENT; ANTITUBERCULAR AGENTS; CHILD; CHILD, PRESCHOOL; HUMANS; INFANT; PRACTICE GUIDELINES AS TOPIC; TUBERCULOSIS;

EID: 69849089024     PISSN: 17460913     EISSN: None     Source Type: Journal    
DOI: 10.2217/fmb.09.39     Document Type: Review

References (111)

1. Nelson LJ, Wells CD: Global epidemiology of childhood tuberculosis. Int. J. Tuberc. Lung Dis. 8, 636-647 (2004).
2. Swaminathan S, Rekha B: Childhood tuberculosis - global epidemiology and the impact of HIV. Paediatr. Respir. Rev. 8, 99-106 (2007).
3. Newton SM, Brent AJ, Anderson S, Whittaker E, Kampmann B: Paediatric tuberculosis. Lancet Infect. Dis. 8, 499-510 (2008).
4. WHO. Guidance for National Tuberculosis Programmes on the Management of Tuberculosis in Children. WHO, Geneva, Switzerland. WHO/HTM/TB/2006.371.
5. Marais BJ, Hesseling AC, Gie RP, Schaaf HS, Beyers N: The burden of childhood tuberculosis and the accuracy of routine surveillance data in a high-burden setting. Int. J. Tuberc. Lung Dis. 10, 259-263 (2006).
6. Starke JR, Jocobs RF, Jereb J: Resurgence of tuberculosis in children. J. Pediatr. 120, 839-855 (1992).
7. Sánchez-Albisua I, Baquero-Artigao F, Del Castillo F, Borque C, García-Miguel MJ, Vidal ML: Twenty years of pulmonary tuberculosis in children: what has changed? Pediatr. Infect. Dis. J. 21, 49-53 (2002).
8. Marais BJ, Gie RP, Schaaf HS, Hesseling AC, Enarson DA, Beyers N: The spectrum of childhood tuberculosis in a highly endemic area. Int. J. Tuberc. Lung Dis. 10, 732-738 (2006).
9. Bhargava SK, Saha MM, Agarwal KN, Rao V: Some observations on the patterns of pulmonary tuberculosis in children. Indian Pediatr. 4(6), 262-266 (1967).
10. Chintu C, Mudenda V, Lucas S et al.: Lung diseases at necropsy in African children dying from respiratory illnesses: a descriptive necropsy study. Lancet 360, 985-990 (2002).
11. McNally LM, Jeena PM, Gajee K et al.: Effect of age, polymicrobial disease, and maternal HIV status on treatment response and cause of severe pneumonia in South African children: a prospective descriptive study. Lancet 369, 1440-1451 (2007).
12. Nunn P, Reid A, De Cock KM: Tuberculosis and HIV infection: the global setting. J. Infect. Dis. 196(Suppl. 1), S5-S14 (2007).
13. Lawn SD, Bekker LG, Middelkoop K, Myer L, Wood R: Impact of HIV infection on the epidemiology of tuberculosis in a peri-urban community in South Africa: the need for age-specific interventions. Clin. Infect. Dis. 42, 1040-1047 (2006).
14. Cotton MF, Schaaf HS, Lottering G, Wever HL, Coetzee J, Nachman S: Tuberculosis exposure in HIV-exposed infants in a high-prevalence setting. Int. J. Tuberc. Lung Dis. 12, 225-227 (2008).
15. Donald PR, Diacon AH: The early bactericidal activity of anti-tuberculosis drugs: a literature review. Tuberculosis 88(Suppl. 1), S75-S83 (2008).
16. Mitchison DA: Role of individual drugs in the chemotherapy of tuberculosis. Int. J. Tuberc. Lung Dis. 4, 796-806 (2000).
17. Donald PR, Schaaf HS: Old and new drugs for the treatment of tuberculosis in children. Paediatr. Respir. Rev. 8, 134-141 (2007).
18. Mitchison DA: How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis. Int. J. Tuberc. Lung Dis. 2, 10-15 (1998).
19. Marais BJ, Gie RP, Schaaf HS, Donald PR, Beyers N, Starke J: Childhood pulmonary tuberculosis - old wisdom and new challenges. Am. J. Resp. Crit. Care Med. 173, 1078-1090 (2006).
20. Kruk A, Gie RP, Schaaf HS, Beyers N, Marais BJ: Symptom-based screening of child tuberculosis contacts: improved feasibility in resource-limited settings. Pediatrics 121, e1646-e1652 (2008).
21. Balcells ME, Thomas SL, Godfrey-Faussett P, Grant AD: Isoniazid preventive therapy and risk for resistant tuberculosis. Emerg. Infect. Dis. 12, 744-751 (2006).
22. Cohen T, Lipsitch M, Walensky RP, Murray M: Beneficial and perverse effects of isoniazid preventive therapy for latent tuberculosis infection in HIV-tuberculosis coinfected populations. Proc. Natl Acad. Sci. USA 103, 7042-7047 (2006).
23. The United States Public Health Service Tuberculosis Prophylaxis Trial collaborators: Prophylactic effects of isoniazid on primary tuberculosis in children. Am. Rev. Tuberc. 76, 942-963 (1957).
24. Smieja MJ, Marchettie CA, Cook DJ, Smaill FM: Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database Syst. Rev. 4, 1-20 (1999).
25. Marais BJ, van Zyl S, Schaaf HS, van Aardt M, Gie RP, Beyers N: Adherence to isoniazid preventive chemotherapy in children: a prospective community based study. Arch. Dis. Child. 91, 762-765 (2006).
26. Van Zyl S, Marais BJ, Hesseling AC, Gie RP, Beyers N, Schaaf HS: Adherence to antituberculosis chemoprophylaxis and treatment in children. Int. J. Tuberc. Lung Dis. 10, 13-18 (2006).
27. Ena J, Valls V: Short-course therapy with rifampin plus isoniazid, compared with standard therapy with isoniazid, for latent tuberculosis infection: a meta-analysis. Clin. Infect. Dis. 40, 670-676 (2005).
28. Spyridis NP, Spyridis PG, Gelesme A et al.: The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study. Clin. Infect. Dis. 45, 715-722 (2007).
29. Priest DH, Vossel LF, Sherfy EA, Hoy DP, Haley CA: Use of intermittent rifampin and pyrazinamide therapy for tuberculosis infection in a targeted tuberculin-testing program. Clin. Infect. Dis. 15, 1764-1771 (2004).
30. Magdorf K, Arizzi Rusche AF, Geiter RJ, O'Brien RJ, Wahn U: Short-course preventive therapy for tuberculosis: a pilot study of rifampin and rifampin-pyrazinamide regimens in children. Am. Rev. Respir. Dis. 143(Suppl.), A120 (1991).
31. Padmini R, Srinivasan S, Nalini P, Mahadevan S: Short course chemotherapy for tuberculosis in children. J. Trop. Ped. 39, 361-364 (1993).
32. Dutt AK, Moers D, Stead WW: Smear and culture negative pulmonary tuberculosis: four month short course therapy. Am. Rev. Resp. Dis. 139, 867-870 (1989).
33. Te Water Naude JM, Donald PR, Hussey GD et al.: Twice weekly vs. daily chemotherapy for childhood tuberculosis. Pediatr. Infect. Dis. J. 19, 405-410 (2000).
34. Al-Dossary FS, Ong LT, Correa AG, Starke JR: Treatment of childhood tuberculosis with a six month directly observed regimen of only two weeks of daily therapy. Pediatr. Infect. Dis. J. 21, 91-97 (2002).
35. Vernon A, Burman W, Benator D et al.: Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Lancet 353, 1843-1847 (1999).
36. Rieder HL, Arnadottir A, Trebucq A, Enarson DA: Tuberculosis treatment: dangerous regimens? Int. J. Tuberc. Lung Dis. 5, 1-3 (2001).
37. Ellard GA, Humphries MJ, Allen BW: Cerebrospinal fluid drug concentrations and the treatment of tuberculous meningitis. Am. Rev. Respir. Dis. 148, 650-655 (1993).
38. Donald PR, Seifert HI: Cerebrospinal fluid concentrations of ethionamide in children with tuberculous meningitis. J. Pediatr. 115, 483-486 (1989).
39. Donald PR, Schoeman JF, van Zyl LE, De Villiers JN, Pretorius M, Springer P: Intensive short course chemotherapy in the management of tuberculous meningitis. Int. J. Tuberc. Lung Dis. 2, 704-711 (1998).
40. Alarcon F, Escalante L, Perez Y, Banda H, Chacon G, Duenas G: Tuberculous meningitis: short course therapy. Arch. Neurol. 47, 1313-1317 (1990).
41. Marais BJ, Pai M: New approaches and emerging technologies in the diagnosis of childhood tuberculosis. Paediatr. Respir. Rev. 8, 124-133 (2007).
42. Theart AC, Marais BJ, Gie RP, Hesseling AC, Beyers N: Criteria used for the diagnosis of childhood tuberculosis at primary health care level in a high-burden, urban setting. Int. J. Tuberc. Lung Dis. 9, 1210-1214 (2005).
43. Marais BJ, Gie RP, Schaaf HS et al.: A refined symptom-based approach to diagnose pulmonary tuberculosis in children. Pediatrics e1350-e1359 (2006).
44. Marais BJ, Cotton M, Graham S, Beyers N: Diagnosis and management challenges of childhood TB in the era of HIV. J. Infect. Dis. 196(Suppl. 1), S76-S85 (2007).
45. Gie RP, Matiru RH: Supplying quality-assured child-friendly anti-tuberculosis drugs to children. Int. J. Tuberc. Lung Dis. 13, 277-278 (2009).
46. Donald PR, Sirgel FA, Venter A et al.: The influence of human N-acetyltransferase genotype on the early bactericidal activity of isoniazid. Clin. Infect. Dis. 39, 1425-1430 (2004).
47. Schaaf HS, Parkin DP, Seifert HI et al.: Isoniazid pharmacokinetics in children treated for respiratory tuberculosis. Arch. Dis. Child. 90, 614-618 (2005).
48. McIlleron H, Willemse M, Werely CJ et al.: Isoniazid plasma concentrations in a cohort of South African children with tuberculosis: implications for international pediatric dosing guidelines. Clin. Infect. Dis. 48(11), 1547-1553 (2009).
49. Schaaf HS, Willemse M, Cilliers K et al.: Rifampin pharmacokinetics in children, with and without human immunodeficiency virus infection, hospitalized for the management of severe forms of tuberculosis. BMC Med. 7(1), 19 (2009).
50. Graham SM, Bell DJ, Nyirongo S, Hartkorn R, Ward SA, Molyneux EM: Low levels of pyrazinamide and ethambutol in children with tuberculosis and impact of age, nutritional status and human immunodeficiency virus infection. Antimicrob. Agents Chemother. 50, 407-413 (2006).
51. Thee S, Detjen A, Wahn U, Magdorf K: Pyrazinamide serum levels in childhood tuberculosis. Int. J. Tuberc. Lung Dis. 12, 1099-1101 (2008).
52. Thee S, Detjen A, Quarcoo D, Wahn U, Magdorf K: Ethambutol in paediatric tuberculosis: aspects of ethambutol serum concentration, efficacy and toxicity in children. Int. J. Tuberc. Lung Dis. 11, 965-971 (2007).
53. Donald PR, Maher D, Maritz JS, Qazi S: Ethambutol dosage for the treatment of children: literature review and recommendations. Int. J. Tuberc. Lung Dis. 10, 1318-1330 (2006).
54. Hines RN, McCarver DG: Pharmacogenomics and the future of drug therapy. Pediatr. Clin. N. Am. 53, 591-619 (2006).
55. Rakesh l, Ramesh Menon P, Kabra SK: Concerns on the dosing of antitubercular drugs for children in RNTCP. Indian Pediatr. 45, 852-854 (2008).
56. Ormerod LP, Skinner C, Wales J: Hepatotoxicity of antituberculosis drugs. Thorax 51, 111-113 (1996).
57. Donald P, Cilliers K, Willemse M et al.: Pyridoxine serum concentrations in children hospitalized with tuberculosis. Int. J. Tuberc. Lung Dis. 11(Suppl. 1), S225 (2007).
58. Steiner P, Rao M: Drug-resistant tuberculosis in children. Semin. Pediatr. Infect. Dis. 4, 275-282 (1993).
59. Schaaf HS, Gie RP, Beyers N: Primary drug-resistant tuberculosis in children. Int. J. Tuberc. Lung Dis. 12, 1149-1155 (2000).
60. Schaaf HS, Marais BJ, Hesseling AC, Gie RP, Beyers N, Donald PR: Childhood drug-resistant tuberculosis in the Western Cape Province of South Africa. Acta Paediatr. 95, 523-528 (2006).
61. Schaaf HS, Marais BJ, Hesseling AC, Brittle W, Donald PR: Surveillance of antituberculosis drug resistance among children from the Western Cape Province of South Africa - an upward trend. Am. J. Pub. Health doi: 10.2105/AJPH.2008.143271 (2009) (Epub ahead of print).
62. Johnson R, Warren R, Strauss OJ et al.: An outbreak of drug-resistant tuberculosis caused by a Beijing strain in the Western Cape, South Africa. Int. J. Tuberc. Lung Dis. 10, 1412-1414 (2006).
63. Marais BJ, Victor TC, Hesseling AC et al.: Beijing and Haarlem genotypes are overrepresented among children with drug-resistant tuberculosis in the Western Cape Province of South Africa. J. Clin. Microbiol. 44(10), 3539-3543 (2006).
64. Schaaf HS, Shean K, Donald PR: Culture confirmed multidrug resistant tuberculosis: diagnostic delay, clinical features and outcome. Arch. Dis. Child. 88, 1106-1111 (2003).
65. LoBue PA, Moser KS: Isoniazid- and rifampin-resistant tuberculosis in San Diego County, California, United States, 1993-2002. Int. J. Tuberc. Lung Dis. 9(5), 501-506 (2005).
66. Schaaf HS, Victor TC, Engelke E et al.: Minimal inhibitory concentration of isoniazid in isoniazid-resistant Mycobacterium tuberculosis isolates from children. Eur. J. Clin. Microbiol. Infect. Dis. 26, 203-205 (2007).
67. Moulding TS: Should isoniazid be used in retreatment of tuberculosis despite acquired isoniazid resistance? Am. Rev. Respir. Dis. 123, 262-264 (1981).
68. Warren RM, Streicher EM, Gey van Pittius NC et al.: The clinical relevance of mycobacterial pharmacogenetics. Tuberculosis 89(3),199-202 (2009).
69. Katiyar SK, Bihari S, Prakash S, Mamtani M, Kulkarni H: A randomised controlled trial of high-dose isoniazid adjuvant therapy for multidrug-resistant tuberculosis. Int. J. Tuberc. Lung Dis. 12(2), 139-145 (2008).
70. WHO: Guidelines for the programmatic management of drug-resistant tuberculosis. Emergency update 2008. WHO, Geneva, Switzerland, 2008. WHO/ HTM/TB/2008.402.
71. Schaaf HS: Drug-resistant tuberculosis in children. S. Afr. Med. J. 97(Part 2), 995-997 (2007).
72. Schaaf HS, Gie RP, Kennedy M, Beyers N, Hesseling PB, Donald PR: Evaluation of young children in contact with adult multidrug-resistant pulmonary tuberculosis: a 30-month follow-up. Pediatrics 109, 765-771 (2002).
73. Bardien S, Human H, Harris T et al.: A rapid method for detection of five known mutations associated with aminoglycoside-induced deafness. BMC Med. Genet. 10, 2 (2009).
74. Bonilla CA, Crossa A, Jave HO et al.: Management of extensively drug-resistant tuberculosis in Peru: cure is possible. PLoS ONE 3(8), e2957 (2008).
75. Ghandi NR, Moll A, Sturm AW et al.: Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area in South Africa. Lancet 368, 1575-1580 (2006).
76. Global Alliance for TB drug development. Handbook of anti-tuberculosis agents. Tuberculosis 88, 85-170 (2008).
77. Zar HJ, Cotton MF, Strauss S et al.: Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomized controlled trial. BMJ 334(7585), 136 (2007).
78. Gray DM, Zar H, Cotton M: Impact of tuberculosis preventive therapy on tuberculosis and mortality in HIV-infected children. Cochrane Database Syst. Rev. (1), CD006418 (2009).
79. Mwinga A, Hosp M, Godfrey-Faussett P et al.: Twice weekly tuberculosis preventive therapy in HIV infection in Zambia. AIDS 12, 2447-2457 (1998).
80. Woldehanna S, Volmink J: Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst. Rev. (1), CD000171 (2004).
81. Churchyard GJ, Fielding K, Charalambous S et al.: Efficacy of secondary isoniazid preventive therapy among HIV-infected Southern Africans: time to change policy? AIDS 17, 2063-2070 (2003).
82. Schaaf HS, Krook S, Hollemans DW, Warren RM, Donald PR, Hesseling AC: Recurrent culture-confirmed tuberculosis in human immunodeficiency virus-infected children. Pediatr. Infect. Dis. J. 24, 685-691 (2005).
83. Violari A, Cotton MF, Gibb DM et al.; CHER Study Team: Early antiretroviral therapy and mortality among HIV-infected infants. N. Engl. J. Med. 359, 2233-2244 (2008).
84. Walters E, Cotton MF, Rabie H, Schaaf HS, Walters LO, Marais BJ: Clinical presentation and outcome of tuberculosis in human immunodeficiency virus infected children on anti-retroviral therapy. BMC Pediatr. 8, 1 (2008).
85. Dhasmana DJ, Dheda K, Ravn P, Wilkinson RJ, Meintjes G: Immune reconstitution inflammatory syndrome in HIV-infected patients receiving antiretroviral therapy: pathogenesis, clinical manifestations and management. Drugs 68, 191-208 (2008).
86. Lawn SD, Wilkinson RJ, Lipman MC, Wood R: Immune reconstitution and 'unmasking' of tuberculosis during antiretroviral therapy. Am. J. Respir. Crit. Care Med. 177, 680-685 (2008).
87. Zampoli M, Kilborn T, Eley B: Tuberculosis during early antiretroviral-induced immune reconstitution in HIV-infected children. Int. J. Tuberc. Lung Dis. 11, 417-423 (2007).
88. Spigelman MK: New tuberculosis therapeutics: a growing pipeline. J. Infect. Dis. 196(Suppl. 1), S28-S34 (2007).
89. Barry PJ, O'Connor TM: Novel agents in the management of Mycobacterium tuberculosis disease. Curr. Med. Chem. 14, 2000-2008 (2007).
90. Rivers EC, Mancera RL: New anti-tuberculosis drugs with novel mechanisms of action. Curr. Med. Chem. 19, 1956-1967 (2008).
91. Zhang Y: Advances in the treatment of tuberculosis. Clin. Pharmacol. Ther. 82, 595-600 (2007).
92. Johnson JL, Hadad DJ, Boom WH et al.: Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int. J. Tuberc. Lung Dis. 10, 605-612 (2006).
93. Ziganshina LE, Squire SB: Fluoroquinolones for treating tuberculosis. Cochrane Database Syst. Rev. (1), CD004795 (2008).
94. Rustomjee R, Lienhardt C, Kanyok T et al.; Gatifloxacin for TB (OFLOTUB) study team: A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int. J. Tuberc. Lung Dis. 12, 128-138 (2008).
95. Park-Wyllie LY, Juurlink DN, Kopp A et al.: Outpatient gatifloxacin therapy and dysglycemia in older adults. N. Engl. J. Med. 354, 1352-1361 (2006).
96. Nuermberger E, Tyagi S, Tasneen R et al.: Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis. Antimicrob. Agents Chemother. 52, 1522-1524 (2008).
97. Burman WJ, Goldberg S, Johnson JL et al.: Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 174, 331-338 (2006).
98. Conde MB, Efron A, Loredo C et al.: Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled Phase II trial. Lancet 373, 1183-1189 (2009).
99. Dorman SE, Johnson JL, Goldberg S et al.: Substitution of noxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. doi: 0.1164/ rccm.200901-0078OC (2009) (Epub ahead of print).
100. Lenaerts AJ, Bitting C, Woolhiser L et al.: Evaluation of a 2-pyridone, KRQ-10018, against Mycobacterium tuberculosis in vitro and in vivo. Antimicrob. Agents Chemother. 52, 1513-1515 (2008).
101. Rustomjee R, Diacon AH, Allen J et al.: Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis. Antimicrob. Agents Chemother. 53, 2831-2835 (2008).
102. Haagsma AC, Ibrahim RA, Wagner MJ et al.: Selectivity of TMC207 toward mycobacterial ATP synthetase as compared with eukaryotic homologue. Antimicrob. Agents Chemother. doi: 10.1128/AAC.01393-08 (2008) (Epub ahead of print).
103. Hu Y, Coates AR, Mitchison DA: Comparison of the sterilising activities of the nitroimidazopyran PA-824 and moxifloxacin against persisting Mycobacterium tuberculosis. Int. J. Tuberc. Lung Dis. 12, 69-73 (2008).
104. Saliu OY, Crismale C, Schander SK, Wallis RS: Bactericidal activity of OPC-67683 against drug-tolerant Mycobacterium tuberculosis. J. Antimicrob. Chemother. 60, 994-998 (2007).
105. Singh R, Manjunatha U, Boshoff HI et al.: PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science 322, 1392-1395 (2008).
106. Sung JC, Garcia-Contreras L, Verberkmoes JL et al.: Dry powder nitroimidazopyran antibiotic PA-824 aerosol for inhalation. Antimicrob. Agents Chemother. 53, 1338-1343 (2009).
107. Burman WJ, Cotton MF, Gibb DM, Walker AS, Vernon AA, Donald PR: Ensuring the involvement of children in the evaluation of new tuberculosis treatment regimens. PLoS Med. 5(8), e176 (2008).
108. Marais BJ, Gie RP, Schaaf HS et al.: The natural history of childhood intra- thoracic tuberculosis - a critical review of the pre-chemotherapy literature. Int. J. Tuberc. Lung Dis. 8, 392-402 (2004).
109. Marais BJ, Donald PR, Gie RP, Schaaf HS, Beyers N: Diversity of disease manifestations in childhood pulmonary tuberculosis. Ann. Trop. Paediatr. 25, 79-86 (2005).
110. Marais BJ: Performing TB research in children - issues to consider. Indian Pediatr. 45, 737-739 (2008).
111. Chintu C, Luo C, Bhat G, Raviglione M, DuPont H, Zumla A: Cutaneous hypersensitivity reactions due to thiacetazone in the treatment of tuberculosis in Zambian children infected with HIV-I. Arch. Dis. Child. 68, 665-668 (1993).